森萱医药(830946) - 2024 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 23.21% to CNY 34,861,755.22 for Q1 2024, down from CNY 45,399,312.04 in Q1 2023[12] - Operating revenue for Q1 2024 was CNY 137,674,996.19, representing a decline of 21.40% compared to CNY 175,152,565.78 in the same period last year[12] - The weighted average return on net assets based on net profit attributable to shareholders was 3.02% for Q1 2024, down from 4.09% in Q1 2023[12] - Total operating revenue for Q1 2024 was CNY 137,674,996.19, a decrease from CNY 175,152,565.78 in Q1 2023, representing a decline of approximately 21.5%[40] - Total operating costs for Q1 2024 were CNY 97,935,912.87, down from CNY 121,282,349.06 in Q1 2023, indicating a reduction of about 19.2%[40] - The net profit for Q1 2024 was CNY 1,260,452.45, an increase from CNY 912,375.25 in Q1 2023, representing a growth of approximately 38%[43] - The total profit for Q1 2024 was CNY 1,735,801.74, an increase from CNY 1,256,211.59 in Q1 2023, representing a growth of approximately 38%[43] - The basic earnings per share for Q1 2024 was CNY 0.0817, down from CNY 0.1063 in Q1 2023, reflecting a decrease of about 23%[42] Cash Flow - The net cash flow from operating activities decreased by 19.86% to CNY 19,833,649.82 in Q1 2024, down from CNY 24,748,327.96 in Q1 2023[12] - Cash received from operating activities increased by 1,684,260.57 yuan, up 168.24% compared to the previous period, mainly due to an increase in interest income[15] - Cash paid for various taxes decreased by 10,316,710.10 yuan, down 46.90%, primarily due to the expiration of tax deferral policies for small and micro enterprises[15] - Cash paid for other operating activities decreased by 3,768,800 yuan, down 42.07%, mainly due to a reduction in transportation costs[15] - The cash inflow from operating activities in Q1 2024 was CNY 115,291,036.73, compared to CNY 140,961,929.11 in Q1 2023, a decrease of approximately 18%[45] - The cash outflow from operating activities in Q1 2024 was CNY 95,457,386.91, down from CNY 116,213,601.15 in Q1 2023, indicating a reduction of about 18%[45] - The total cash outflow from operating activities in Q1 2024 was 1,855,899.69, down from 3,510,686.41 in Q1 2023, reflecting a decrease of approximately 47.3%[48] - The cash flow from operating activities netted a total of 1,435,065.57 in Q1 2024, indicating a positive trend in operational cash generation[47] Assets and Liabilities - Total assets increased by 1.75% to CNY 1,350,576,245.07 as of March 31, 2024, compared to CNY 1,327,313,296.09 at the end of 2023[12] - The company's debt-to-asset ratio decreased to 7.69% in Q1 2024 from 8.87% at the end of 2023[12] - Total liabilities decreased to CNY 103,905,317.35 as of March 31, 2024, from CNY 117,735,441.12 at the end of 2023, a reduction of approximately 11.8%[36] - The company's total equity increased to CNY 1,246,670,927.72 as of March 31, 2024, compared to CNY 1,209,577,854.97 at the end of 2023, representing an increase of about 3.1%[36] - The total liabilities to equity ratio improved to approximately 8.33 as of March 31, 2024, down from 9.73 at the end of 2023, indicating a strengthening of the company's financial position[36] Investments and Expenses - Construction in progress increased by 138.00% to CNY 23,454,152.42, primarily due to investments in new production projects[13] - Research and development expenses increased to CNY 7,116,442.26 in Q1 2024, compared to CNY 5,774,630.02 in Q1 2023, reflecting a growth of approximately 23.2%[40] - The company reported a fair value gain of CNY 594,616.44 in Q1 2024, compared to CNY 694,750.68 in Q1 2023, reflecting a decrease of about 14%[43] - The company experienced a credit impairment loss of CNY -455.00 in Q1 2024, compared to CNY 410.00 in Q1 2023, indicating a worsening in credit quality[43] Shareholder Information - The total number of ordinary shares at the end of the period was 426,918,340, with 99.9517% being unrestricted shares[20] - The largest shareholder, Jinghua Pharmaceutical Group Co., Ltd., holds 308,724,340 shares, accounting for 72.3146% of the total shares[22] - The company did not have any pledged or judicially frozen shares during the reporting period[23] Other Financial Metrics - The company reported a total of CNY 24,461,685.30 in assets under pledge or mortgage, accounting for 1.81% of total assets[30] - The company executed daily related transactions with a total expected amount of CNY 15 million for raw materials, but only CNY 25,530.98 was incurred in the reporting period[29] - The company recorded CNY 1,594,876.10 in sales of products and services against an expected amount of CNY 40 million for the year[29] - The company's cash and cash equivalents increased to CNY 513,461,081.25 as of March 31, 2024, compared to CNY 505,949,141.18 at the end of 2023[34] - The company’s accounts receivable rose to CNY 42,131,543.54 from CNY 34,237,921.14, indicating a growth in credit sales[34] - The company’s fixed assets decreased to CNY 341,639,869.66 from CNY 352,114,874.54, reflecting asset depreciation[34] - The company’s inventory stood at CNY 146,378,353.94, slightly up from CNY 145,993,690.74, indicating stable stock levels[34]